Cell therapy manufacturer NeoStem and contract manufacturer Invetech have agreed to develop a new closed processing system for cell therapy manufacturing.
Horizon says its £6m (€7.7m) purchase of Austrian biotech Haplogen Genomics means it can produce cell lines ten times faster than before using a haploid gene platform.
The hype around developing new CAR-T (Chimeric Antigen Receptor transduced T) cell therapies, which can fight cancers by modifying patients’ immune cells, seemed to hit a new high this week, with two partnerships and an acquisition.
The $20m funding led by Pfizer Venture Investments will help advance a platform to make Probodies which CytomX says offers more precise tumour targeting than antibodies.
Sotio has selected local CRO Accord Research to carry out Phase I/II trials on its dendritic cell vaccines to treat patients with lung cancer in the Czech Republic.
Cancer and infectious disease immunotherapy developer Argos Therapeutics is collaborating with Saint-Gobain’s Performance Plastics division, to design, integrate and scale production of a range of disposables for use in the manufacturing of Argos’ lead...
Flu vaccine maker Protein Sciences, and Japan-based UMN Pharma and IHI Corp. have entered into an agreement to assess the feasibility of sourcing the active ingredients of Flublok influenza vaccine from Japan.
Korean and Harvard University scientists have developed a way to non–surgically inject programmable biomaterial to deliver a 3D vaccine that can more effectively treat diseases like cancer or HIV.
In a reversal from three years ago, the Court of Justice of the European Union (CJEU) ruled on Thursday that an organism incapable of developing into a human being is not a human embryo and may be patented.
Bruker Corp will pay $2.4m to settle US SEC charges that employees improperly funded Chinese officials' sightseeing trips to win analytical tech contracts at state labs.
Biopharma heavyweights Amgen, Pfizer and a number of other companies offered their unique takes on the biosimilar draft guidance from the EMA, calling for more clarity and some new additions before the final draft takes effect.
Richard the III was blond, blue-eyed and may owe a substantial parking fine based on new genetic research that solves a 529-year old missing persons case.
There is an upsurge in biopharma demand for cell and gene therapy applications, says Transposagen as it inks a deal with Janssen to develop allogeneic Chimeric Antigen Receptor (CAR) T-cells.
Merck has agreed to research, develop, manufacture, and distribute NewLink’s investigational Ebola vaccine candidate, which is currently in Phase I trials.
Amgen has completed construction of its first $200m next-gen biomanufacturing facility in Singapore, which is outfitted with single-use technology to allow for greater flexibility.
With the goal of developing a thermostable tuberculosis vaccine, IDRI (Infectious Disease Research Institute) was awarded a contract from the NIH’s National Institute of Allergy and Infectious Diseases that could be worth up to $11.9m.
UK researchers working with GSK say a newly identified immune cell communication mechanism could explain why some drugs don’t work and drive development of smaller, large molecule meds.
Collaboration does not mean drugmakers have started playing nice, it’s just that the pain of shared problems has become unbearable according to TransCelerate Biopharma CEO, Dalvir Gill.
Drug companies are looking for ways to put biologics in topical creams or “zap” them into skin using electricity as more large molecules come off patent.
There is no evidence that Ebola arrived on Earth from the stars, say a number of virologists, debunking media speculation that viruses had their origins in the Milky Way.
Isis Pharmaceuticals and AstraZeneca have expanded their partnership to develop novel delivery methods for antisense oligonucleotides in order to target the desired tissue more effectively.
Lack of funding is threatening development of a nasal spray vaccine shown to provide long-term protection for non-human primates against the Ebola virus, the lead researcher told this publication in an exclusive interview.
Like the US and EU, China’s SFDA is looking to ensure that approved biosimilars are proven to be similar to their reference drugs, according to an unofficial translation of the guideline by BioCentury.
Regenerative medicine company ViaCyte has been granted a US patent for the manufacture of human pancreatic progenitor cells from definitive endoderm cells.
GSK is keeping its Ebola vaccine production in-house, despite previously leaked documents which suggested the company could not ramp up volume of BS-2 manufacturing without impacting its other vaccine lines.
Addicts struggling to kick a meth habit could be helped by gene therapy according to the team behind a US National Institutes of Health funded project.
The World Health Organisation says a meeting between drugmakers and high-level government representatives last week has yielded plans to fast-track scale-up of Ebola vaccines in the face of incomplete trials and leaked production problems.
The UK beats Finland for business opportunities according to the CEO of microbial growth system developer BioSilta, who said moving the firm to St. Ives, Cambridgeshire has improved its access to larger markets.
Personalized immunotherapy developer Argos Therapeutics has broken ground on a new 100,000 square-foot biomanufacturing facility in Durham, North Carolina.
A bioanalytical consultant has stressed the importance of drug developers testing commercial off-the-shelf (COTS) software following the discovery of potential issues with Thermo Scientific’s bioequivalence Kinetica platform.
Biopharmas struggle to comply with GMP requirements for personalised meds and the outstanding questions mean some are reluctant to invest according to German firm immatics.
Ramesses II didn't need Enbrel, Remicade, Humira or any other TNFα blocker according to a study that rejects the idea the pharaoh was plagued, all puns intended, by ankylosing spondylitis.
Nova’s vaccine stabilisation device, which enables vaccines to be dried and stabilized across a wide range of temperatures, has been awarded a US patent, though one researcher questions the utility of the device.
Making active pharmaceutical ingredients (API) is a dirty business and you’d have to be pretty green to believe claims drug industry 'demand' will create a $100bn market for environmentally-friendly production methods by 2020.
As more than half a dozen companies are now vying to help treat and vaccinate Ebola victims in West Africa, where nearly 3,000 people have died from the illness, GlaxoSmithKline is taking the lead in getting product manufactured.
